Breakthrough SARS-CoV-2 infections, morbidity, and seroreactivity following initial COVID-19 vaccination series and additional dose in patients with SLE in New York City

Lancet Rheumatol. 2022 Sep;4(9):e582-e585. doi: 10.1016/S2665-9913(22)00190-4. Epub 2022 Jul 12.

Authors

Amit Saxena¹, Alexis J Engel¹, Brittany Banbury¹, Ghadeer Hasan¹, Nicola Fraser¹, Devyn Zaminski¹, Mala Masson¹, Rebecca H Haberman¹, Jose U Scher¹, Gary Ho¹, Jammie Law¹, Paula Rackoff¹, Chung-E Tseng¹, H Michael Belmont¹, Robert M Clancy¹, Jill P Buyon¹, Peter M Izmirly¹

Affiliation

¹ Division of Rheumatology, Department of Medicine, New York University Grossman School of Medicine, New York, NY 10016, USA.

No abstract available

Grants and funding

P50 AR070591/AR/NIAMS NIH HHS/United States